Search Results - "Grimm, Sean Aaron"

A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT) by Kumthekar, Priya, Dixit, Karan, Grimm, Sean Aaron, Lukas, Rimas Vincas, Schwartz, Margaret A., Rademaker, Alfred, Sharp, Laura, Nelson, Valerie, Raizer, Jeffrey J.

“…Abstract only 2070 Background: Brain metastases (BM) are the most common intracranial malignancy with overall a poor prognosis estimated at approximately 4…”
Get full text

A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy by Dixit, Karan, Singer, Lauren, Grimm, Sean Aaron, Lukas, Rimas V, Schwartz, Margaret A, Rademaker, Alfred, Zhang, Hui, Kocherginsky, Masha, Chernet, Sofia, Sharp, Laura, Nelson, Valerie, Raizer, Jeffrey J, Kumthekar, Priya

“…Patients with solid tumor brain metastases that progress after whole-brain radiation have limited options. This prospective trial investigated the efficacy,…”
Get full text

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma by Kumthekar, Priya, Grimm, Sean Aaron, Aleman, Roxanne T, Chamberlain, Marc C, Schiff, David, Wen, Patrick Y, Iwamoto, Fabio Massaiti, Gursel, Demirkan Besim, Reardon, David A, Purow, Benjamin, Kocherginski, Masha, Helenowski, Irene, Raizer, Jeffrey J

Get full text

A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01 by Raizer, Jeffrey J., Grimm, Sean Aaron, Penas-Prado, Marta, Tremont-Lukats, Ivo, Yung, W. K. Alfred, Avgeropoulos, Nicholas George, Walbert, Tobias, Loghin, Monica Elena, Gilbert, Mark R.

“…Abstract only…”
Get full text

Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma by Grimm, Sean Aaron, Kumthekar, Priya, Chamberlain, Marc C., Schiff, David, Wen, Patrick Y., Iwamoto, Fabio Massaiti, Reardon, David A., Purow, Benjamin, Raizer, Jeffrey J.

“…Abstract only…”
Get full text

Phase II study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas by Kumthekar, Priya, Grimm, Sean Aaron, Marymont, MaryAnne H., Mehta, Minesh P., Chandler, James, Muro, Kenji, Jovanovic, Borko, Helenowski, Irene B., McCarthy, Katie, Raizer, Jeffrey J.

“…Abstract only…”
Get full text

A phase II trial evaluating tumor penetration of bortezomib in patients with recurrent malignant gliomas treated prior to surgery and then treated with bortezomib and temozolomide postoperatively by Raizer, Jeffrey J., Grimm, Sean Aaron, Levy, Robert M., Muro, Kenji, Rosenow, Joshua M., Chandler, James, Bredel, Markus

“…Abstract only 2035 Background: NF-Kappa B is one of the mechanisms of resistance for malignant gliomas. A few trials have assessed bortezomib in the treatment…”
Get full text

Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma by Lee, Eudocia Quant, Reardon, David A., Schiff, David, Drappatz, Jan, Muzikansky, Alona, Grimm, Sean Aaron, Norden, Andrew David, Nayak, Lakshmi, Beroukhim, Rameen, Rinne, Mikael L., Chi, Andrew S., Batchelor, Tracy, Hempfling, Kelly, McCluskey, Christine Sceppa, Smith, Katrina H., Gaffey, Sarah C., Wrigley, Brendan, Raizer, Jeffrey J., Wen, Patrick Y.

“…Abstract only…”
Get full text

Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome by Curry, Richard Charles, Correa, Denise, Raizer, Jeffrey J., Grimm, Sean Aaron, Lai, Rose, Schiff, David, Grant, Barbara W., Reiner, Anne S., Panageas, Katherine, Yahalom, Joachim, DeAngelis, Lisa Marie, Abrey, Lauren E., Morris, Patrick Glyn, Omuro, Antonio Marcilio Padula

“…Abstract only 2006 Background: After promising early results in the pilot phase (N= 30) reported by Shah 2007, we report on final results of a multicenter…”
Get full text

Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma by Lee, Eudocia Quant, Reardon, David A., Schiff, David, Drappatz, Jan, Muzikansky, Alona, Hammond, Samantha, Grimm, Sean Aaron, Norden, Andrew David, Beroukhim, Rameen, McCluskey, Christine Sceppa, Chi, Andrew S., Batchelor, Tracy, Smith, Katrina H., Gaffey, Sarah C., Gerard, Mary, Snodgrass, Susan M., Raizer, Jeffrey J., Wen, Patrick Y.

“…Abstract only 2013 Background: Bevacizumab is frequently used to treat recurrent GBM, but responses are generally not durable. Panobinostat is a histone…”
Get full text

BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation by Raizer, Jeffrey J., Giglio, Pierre, Hu, Jethro Lisien, Groves, Morris D., Merrell, Ryan, Conrad, Charles A., Phuphanich, Surasak, Puduvalli, Vinay K., Loghin, Monica Elena, Paleologos, Nina, Yung, W. K. Alfred, Vaillant, Brian D., Rudnick, Jeremy David, Chamberlain, Marc C., Vick, Nicholas, Grimm, Sean Aaron, Tremont-Lukats, Ivo, De Groot, John Frederick, Aldape, Kenneth D., Gilbert, Mark R.

“…Abstract only 2019^ Background: Patients (pts) with GBM with unmethylated MGMT have a worse prognosis than those with methylated MGMT. Novel approaches for…”
Get full text